法莫替丁预防奥氮平引起体质量增加的研究

目的 探讨H2受体拮抗剂法莫替丁在预防奥氮平引起的体质量增加中的疗效.方法 选择40例符合中国精神障碍分类与诊断标准的首发精神分裂症患者,随机分为奥氮平合用法莫替丁组和奥氮平合用安慰剂组,均治疗观察8周.于治疗前和治疗后2周、4周、8周测身高、体质量,计算体重指数(BMI)及8周内体质量增加超过自身基线体质量7%的患者比例.采用阳性症状评定量表(SAPS)和阴性症状评定量表(SANS)评定疗效.结果 两组患者的体质量、BMI:治疗后各时点均有增加,与治疗前比较差异有统计学意义(P＜0.05).奥氮平加法莫替丁组和奥氮平组治疗8周末体质量分别增加了3.7 kg,BMI各增加了2.5 kg/cm2和2.6 kg/cm2.治疗后各时点,两组患者的体质量、BMI增加程度比较差异无统计学意义(P＞0.05).治疗8周末,体质量增加超过基线体质量7%的患者比例两组差异无统计学意义(P＞0.05).治疗8周末,SAPS、SANS评分显著下降(P＜0.05);SAPS与SANS分值与基线的差值无组间差异(P＞0.05).结论 合用H2-拮抗剂法莫替丁不能减轻奥氮平引起的体质量增加.

A study of fomotidine preventing weight gain olanzapine-induced

Objeetive To study the therapeutic effect of the H2 antagonist fomotidine on preventing weight gain olanzapine-induced.Methods Forty first-episode CCMD-3 schizophrenia patients were randomly allocated to received either famotidine or placebo in addition to olanzapine for 8 weeks.Their body weights and heights were measured before treatment and 2 weeks,4 weeks,8 weeks after treatment to calculate the body mass index and the percentage of patients gained more than 7% of initial bpdy weight after 8 weeks.SAPS and SANS were selected to evaluate the therapeutic effect.Results While the weight and the body mass index of patients in two groups after 2 weeks,4 weeks,8 weeks post-treatment increased significantly compared with those of pre-treatment(P＜0.05).The weight of patients in two groups gained 3.7kg at the edd of 8 weeks,and the BMI increased 2.5 or 2.6 kg/cm2,reapectively.However 8 weeks later,the difference between two groups wan not significant(P＞0.05).The difference between two groups on the percentage of patients gained more than 7% of initial body weight at the end of 8 weeks Wan not significant(P＞0.05).The sCOres of SAPS and SANS at the end of 8 weeks decreased significantly compared with those of the baseline(P＜0.05),but the difference between two groups was not significant(P＞0.05).Conclusion Allocated to the H2 antagonist fomotidine could not reduce weight gain olanzapine-induced.